Scarica l'app Stockscreener
695.18
4.20%
28.01
Dopo l'orario di chiusura:
690.00
-5.18
-0.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$667.17
Aprire:
$676.93
Volume 24 ore:
900.05K
Relative Volume:
0.93
Capitalizzazione di mercato:
$72.88B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
16.94
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+2.96%
1M Prestazione:
+9.84%
6M Prestazione:
-7.45%
1 anno Prestazione:
+24.44%
Intervallo 1D:
$676.46
$696.74
Intervallo di 1 settimana:
$637.80
$696.74
Portata 52W:
$541.00
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
695.18 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
490.39 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
872.23 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.86 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.41 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class ActionContact The Gross Law Firm - PR Newswire
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView
REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses - PR Newswire
(REGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses - PR Newswire
Regeneron Says Drug Approval Irrelevant In Antitrust Case - Law360
Regeneron on track to build in Saratoga - The Daily Gazette
Regeneron Pharmaceuticals (REGN) Q2 2026 Preview: EPS Est. $10.26, Reports July 30 - AlphaStreet
REGN DEADLINE: Levi & Korsinsky Reminds Regeneron - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire Inc.
Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
$REGN Lawsuit Notice: BFA Law Reminds Regeneron Investors - GlobeNewswire
14,700 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Orbimed Advisors LLC - MarketBeat
3,883 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Lombard Odier Asset Management Switzerland SA - MarketBeat
Renaissance Technologies LLC Has $51.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Family Manage LLC - MarketBeat
Entropy Technologies LP Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN) - simplywall.st
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lombard Odier Asset Management Europe Ltd Sells 3,124 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Sei Investments Co. Buys 18,403 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Arrowstreet Capital Limited Partnership Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of September 14, 2026 Deadline - ACCESS Newswire
GC Wealth Management RIA LLC Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Lido Advisors LLC - MarketBeat
Epoch Investment Partners Inc. Has $184.45 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock trades steadily as recent Eylea growth and pipeline advances frame valuation - AD HOC NEWS
Cannell & Spears LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron: I’m Not Concerned About The Declining ROIC And Operating Margins (NASDAQ:REGN) - Seeking Alpha
Regeneron Q2 Earnings Preview: Not Expecting MiraclesAt Least In The Short Term (REGN) - Seeking Alpha
TrumpRx.gov Savings Top $700 Million as Praluent Added at 60% DiscountNews and Statistics - IndexBox
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure - GlobeNewswire Inc.
The Scientist With 1,000 Patents Fueling a Drug Powerhouse - WSJ
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate FailureHBSS - PR Newswire
Regeneron stock trades near record levels as Eylea and Dupixent drive revenue growth - AD HOC NEWS
$REGN Fraud Notification: Regeneron Sued for Fraud Over - GlobeNewswire
Gibbs Wealth Management Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Bank of Nova Scotia - MarketBeat
Bessemer Group Inc. Sells 2,653 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Urged to Join Class Action Before September 14, 2026Contact Levi & Korsinsky - ACCESS Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. LawsuitREGN - Morningstar
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a - GlobeNewswire
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.87%
3.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):